Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Wakim covers the Healthcare sector, focusing on stocks such as Amplia Therapeutics, CSL, and Neuren Pharmaceuticals Limited. According to TipRanks, Wakim has an average return of -10.2% and a 28.57% success rate on recommended stocks.
Currently, the analyst consensus on Microba Life Sciences Limited is a Strong Buy with an average price target of A$0.22, which is a 124.49% upside from current levels. In a report released on August 14, Canaccord Genuity also maintained a Buy rating on the stock with a A$0.19 price target.
MAP market cap is currently A$59.07M and has a P/E ratio of -3.06.